Endicott J et al. – Quetiapine fumarate (quetiapine XR) 150 mg/day (acute studies) and 50–300 mg/day (maintenance study) improved quality of life, overall functioning, and sleep quality in patients with generalized anxiety disorder (GAD).

• This is a report of a pooled analysis from three acute 8-week, randomized, placebo-controlled, fixed-dose (50, 150, 300 mg/day) studies and a 52-week maintenance flexible dose (50-300 mg/day) study of quetiapine XR monotherapy in patients with GAD.
• Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) percent maximum total scores (items 1-14), item 15 ("satisfaction with medication"), item 16 ("overall life satisfaction"), and Pittsburgh Sleep Quality Index (PSQI) global scores are reported.
• Sheehan Disability Scale (SDS) total scores were also assessed (maintenance study only).

• The acute studies showed significant improvements at week 8 in Q-LES-Q-SF percent maximum total score with quetiapine XR 150 mg/day (P < 0.001) and item 16 with quetiapine XR 50 (P < 0.05) and 150 mg/day (P < 0.001) versus placebo; PSQI global scores significantly improved with quetiapine XR 50, 150, and 300 mg/day versus placebo (P < 0.001).
• The maintenance study showed significant benefits versus placebo with quetiapine XR 50–300 mg/day in Q-LES-Q-SF percent total score, item 15 and item 16 scores, PSQI global score, and SDS total score.